Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Equivalents (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Cash & Equivalents data on record, last reported at $86.2 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 46.5% year-over-year to $86.2 million; the TTM value through Sep 2025 reached $86.2 million, up 46.5%, while the annual FY2024 figure was $57.3 million, 29.24% down from the prior year.
  • Cash & Equivalents reached $86.2 million in Q3 2025 per FBIO's latest filing, up from $74.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $305.7 million in Q4 2021 and bottomed at $57.3 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $155.7 million, with a median of $91.3 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: surged 2500.44% in 2021, then tumbled 68.64% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $305.7 million in 2021, then tumbled by 41.69% to $178.3 million in 2022, then tumbled by 54.6% to $80.9 million in 2023, then fell by 29.24% to $57.3 million in 2024, then skyrocketed by 50.56% to $86.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $86.2 million in Q3 2025, $74.4 million in Q2 2025, and $91.3 million in Q1 2025.